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Background: Studies on health-related quality of life are based on the increasingly evident need for medical 
care not to be limited to preventing death, but to focus instead on the value of health.
Objective: This study aimed to measure the health-related quality of life in hemophilia, using the Hemophilia-
Specific Quality of Life (Haem-A-QoL) questionnaire and describe the socioeconomic characteristics and 
health conditions of these patients.
Methods: The Brazilian version of the Hemophilia-Specific Quality of Life questionnaire was administered to 
hemophiliac adults, treated in an on-demand regime at the Juiz de Fora Regional Blood Center - HEMOMINAS 
Foundation. The patients were interviewed about demographic and socioeconomic data and their understanding 
of the questionnaire. Clinical data were collected from medical records. The Mann-Whitney U test was used 
for statistical analysis. The level of significance was set for p-values < 0.05. Statistical analysis was performed 
using the Statistical Package for the Social Sciences (SPSS, version 15.0).
Results: Thirty-nine patients were evaluated. The mean age was 36.8 years. 84.6% had hemophilia A; 20.5% of 
the patients had hemophilia classified as mild, 41% as moderate and 38.5% as severe. The records of 10.5% of the 
patients registered seropositivity for anti-HIV and 57.9% for anti-HCV. Target joints were detected in 69.2%. The 
mean total Hemophilia-Specific Quality of Life score was 35.55. ‘Sports and leisure’ and ‘Physical health’ were the 
most impaired dimensions and the dimension ‘Relationship and partners’ was the least impaired. The Hemophilia-
Specific Quality of Life scores showed good discriminant validity for hemophilia severity (p-value = 0.001), HIV-
infection (p-value = 0.02), HCV-infection (p-value = 0.01) and the presence of target joints (p-value < 0.001).
Conclusion: Health-related quality of life in hemophilia, measured by the Hemophilia-Specific Quality of Life 
questionnaire, was influenced by the presence of arthropathy and infectious diseases transmitted by blood 
products. Rehabilitation measures should be encouraged in order to improve the quality of life of these patients.
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Introduction
Studies on health-related quality of life (HRQoL) are based on the increasingly evident 
need for medical care not to be limited to preventing death, but to focus instead on the value 
of health(1). HRQoL can be influenced by factors such as illness and its treatment, how the 
person deals with his or her problem, and access to care(2). In the case of hemophilia, the 
major issues are the restrictions on physical activities, concern about bleeding that might be 
life-threatening, the development of arthropathy, the need for orthopedic procedures, and now, 
much less frequently, infectious diseases transmitted by blood or blood products(3,4).
HRQoL can be assessed using validated sensitive and specific instruments whose data 
are reproducible and are influenced by age and by time; these instruments should also consider 
the multidimensional nature of the quality of life, the physical and psychological components 
of the patient’s perception of well-being(5). It is also important, for the questionnaire to be 
useable internationally, that is, it be translated and standardized for the different cultures that 
the translations target(6).
As clinical evaluations may not be sufficient to adequately characterize the morbidity 
associated with hemophilia(7,8), the present study aimed to measure HRQoL in adults with 
hemophilia at the Regional Blood Center of Juiz de Fora using the Brazilian version of the 
Hemophilia-Specific Quality of Life (Haem-A-QoL) questionnaire. It also aimed to describe 
socioeconomic aspects and health conditions of these individuals in the context in which the 
Haem-A-QoL was assessed.
Methods
This was an observational, cross-sectional study carried out at the Regional Blood Center 
of Juiz de Fora (HRJF), Minas Gerais, after approval by the Ethics Research Committee of the 
HEMOMINAS Foundation. Informed consent was obtained from all patients involved. The 
inclusion criteria were to be male, 18 years or older, level of clotting factor VIII or IX less than 
or equal to 30%, and on hemophilia treatment in an on-demand protocol connected to the HRJF.
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Participants were asked to complete the Brazilian version 
of the Haem-A-QoL questionnaire used with the expressed 
permission of the Haemo-QoL Group. They were then interviewed 
about the comprehensibility of the questions contained in the 
instrument, and about their demographic and socioeconomic 
data (age, self-reported skin color, education level, marital 
status, main occupation, personal and family income, receipt 
of social security benefits). Furthermore, data from medical 
records on hemophilia and comorbidities were collected, which 
included type and severity of hemophilia and the presence of 
clotting factor inhibitors, presence of human immunodeficiency 
virus antibodies (anti-HIV), Hepatitis C virus antibodies (anti-
HCV) and target joints, considered by Gilbert as the initial 
stage of hemophilic arthropathy(9). Data were also collected 
on the treatment of coagulopathies, such as: age at diagnosis, 
participation in the emergency home infusion program, physical 
activity, physiotherapy, and the use of clotting factors in the 
previous 12 months.
The Haem-A-QoL Questionnaire was compiled using data 
from focus groups of adults with hemophilia who were asked 
about their perceptions of their health conditions and treatment. 
There are 46 items divided into ten dimensions: physical health, 
feelings, self-perception, sports and leisure, work and school, 
coping, treatment, future, family planning and relationships/
partners(10). The Haem-A-QoL was initially validated in Italy 
with 233 hemophilia patients. The psychometric characteristics 
included good reliability, high convergent validity with the 
SF-36 questionnaire, and high discriminant validity regarding 
the severity of hemophilia and the presence of infections(11). 
The questionnaire was translated into Portuguese by the Mapi 
Research Institute and its cross-cultural validity was established 
with positive results from clinical reviews in 17 languages, 
including Portuguese(12). The calculation of the score is performed 
by transforming the scores achieved in each dimension, as well 
as the total score, on scales ranging from zero to 100, with zero 
representing the best HRQoL(13).
Statistical analysis
First, the Kolmogorov-Smirnov test with Lilliefors 
correction was performed. This revealed the non-normality 
of the data. The Mann-Whitney U Test was used to compare 
the mean HRQoL scores. Spearman correlation analyses were 
conducted to evaluate the relationship between the Haem-
A-QoL scores, patient age, and consumption of clotting 
factor concentrates in the previous 12 months. The adopted 
significance level was 5%. Reliability analysis was employed 
to determine the internal consistency with a target minimum 
of 0.7 for Cronbach’s alpha coefficient. Statistical analysis 
was performed using the Statistical Package for the Social 
Sciences program (SPSS, version 15).
Results
Of 60 patients eligible for the study at this blood center, 
one was excluded before data collection began due to severe 
cognitive impairment resulting from central nervous system 
Table 1 - Demographic and socioeconomic characteristics of patients with 
hemophilia treated at the Regional Blood Center of Juiz de Fora
Variable n %
Age
18 to 29 years 17 43.6
30 to 59 years 17 43.6
60 years or more 5 12.8
Self-reported skin color
White 23 59




Single / divorced 26 66.7
Married / stable union 13 33.3
Distance between home and the blood center
0 to 30 km 18 46.2
More than 30 km 21 53.8
Schooling
0 to 4 years 9 23.1
5 to 8 years 9 23.1
9 to 11 years 14 35.9
12 years or more 7 17.9
Personal income in the previous month
Up to 1 minimum wage 20 51.3
1 to 3 minimum wages 14 35.9
More than 3 minimum wages 5 12.8
Family income in the previous month
Up to 2 minimum wages 12 30.8
2 to 5 minimum wages 15 38.5
More than 5 minimum wages 5 12.8
Unable to answer 7 17.9






hemorrhage, 13 were not located due to outdated records and 
seven refused to participate in the study. Thus, 39 patients (65% 
of those eligible) completed the Haem-A-QoL questionnaire 
between May and November 2011. Participant ages ranged 
from 18 to 79 years (mean: 36.8 years; standard deviation: 
16.8 years). The patients’ demographic and socioeconomic 
characteristics are described in Table 1.
Health conditions
Of the 39 participants, 33 had hemophilia A, and six had 
hemophilia B. In eight cases (20.5%) hemophilia was classified 
as mild (level of clotting factor VIII or IX between 5 and 30%), 
in 16 (41%) as moderate hemophilia (level of clotting factor VIII 
or IX between 1 and 5%), and in 15 cases (38.5%) as severe 
hemophilia (level of clotting factor VIII or IX less than 1%).
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Age at diagnosis ranged from 0 to 67 years, and in 58.8% 
of the patients the diagnosis was made after two years of life. 
Comorbidities reported by the patients were: asthma (10.3%), 
arthritis (2.6%), cancer (2.6%), heart disease (2.6%), depression 
(12.8%), hypertension (17.9%), chronic low back pain (15.4%), 
and smoking (28.9%); 66.7% considered themselves sedentary and 
15.4% had a body mass index greater than 25 kg/m2. Records of four 
patients (10.5%) showed seropositivity for anti-HIV and 22 (57.9%) 
for anti-HCV. Of 29 participants who had up-to-date test records, the 
presence of clotting factor inhibitor was detected in only one patient 
with hemophilia A (3.4%) and in no patients with hemophilia B. 
These results differ markedly from those released by the Ministry of 
Health in 2012, where 8.3% of patients with hemophilia A and 2.2% 
of patients with hemophilia B showed the presence of inhibitors(14).
The consumption of clotting factor VIII concentrate in 
the previous 12 months was quite variable. Among patients 
with moderate hemophilia A, it ranged from zero to 198,250 
international units (IU), with an average of 51,625 IU; whereas 
among patients with the severe form of coagulopathy, consumption 
ranged from 14,750 to 174,250 IU, averaging 63,683.3 UI. Of 
the 31 patients with severe or moderate hemophilia, 22 (70.96%) 
were participating in the program for home infusions of factor 
concentrates in emergency situations.
The presence of target joints was detected in 69.2% of 
patients, i.e., the occurrence of three or more hemarthroses in 
the same joint in the six months preceding the study. However, 
only 20.5% of the study participants had received physiotherapy 
treatment in the previous 12 months, despite all the currently 
recognized benefits in the physiotherapeutic approach to 
rehabilitation for patients with hemophilia(15).
Health-related quality of life
The average Haem-A-QoL total score was 35.33, ranging 
from 0 to 79.54. The dimensions ‘Sports and Leisure’ and ‘Physical 
Health’ had the highest averages (49.89 and 43.30, respectively) 
indicating poorer quality of life, and the dimension ‘Relationships 
and Partners’ was the least impaired dimension among the 
participants (mean 17.52). Table 2 shows the mean scores of the 
Haem-A-QoL questionnaire, in total and by dimension.
Table 2 - Mean scores and internal consistency of the dimensions that comprise the Hemophilia-Specific Quality 
of Life Index (Haem-A-QoL) of patients with hemophilia treated at the Regional Blood Center of Juiz de Fora
Dimension n valid Mean Minimum Maximum Standard deviation
Cronbach’s 
alpha coefficient
Physical health 39 43.30 0 95.00 29.58 0.72
Feeling 39 38.56 0 100.00 31.06 0.77
View of yourself 39 37.43 0 85.00 25.25 0.74
Sports and leisure 37 49.89 0 100.00 35.19 0.73
Work and school 27 29.62 0 93.75 27.44 0.83
Dealing 38 31.35 0 100.00 30.10 0.13
Treatment 39 35.47 0 78.12 23.08 0.71
Future 39 39.42 0 90.00 26.72 0.89
Family planning 32 21.41 0 100.00 33.37 0.71
Relationship/ partners 39 17.52 0 100.00 31.69 0.68
Total 39 35.33 0 79.54 20.45 0.90
The Cronbach’s alpha coefficient for the instrument overall 
was 0.90. While in the ‘Coping’ dimension the alpha was 0.13, in 
the other dimensions it ranged from 0.68 to 0.89 in the analysis of 
internal consistency (Table 2).
When the Haem-A-QoL was assessed according to 
hemophilia severity, for patients with severe or moderate 
hemophilia, the dimensions ‘Sports and Leisure’ and ‘Physical 
Health’ were the most impaired. Yet among patients with mild 
hemophilia, the dimension ‘Coping’ showed a quite high average 
that was divergent from other areas (Figure 1).
Figure 1 - Means for the Hemophilia-Specific Quality of Life (Haem-A-
QoL) dimensions by hemophilia severity
The demographic, socioeconomic, and clinical characteristics 
that showed a statistically significant association with Haem-A-
QoL are described in Table 3. The presence of target joints was 
strongly associated with the total score. The average was 24.56 
when one or more target joints were present and 9.75 when there 
was no joint repeatedly affected by hemarthroses (p-value < 0.001).
The Brazilian version of the Haem-A-QoL was shown to 
have good discriminant validity between patients with positive 
and negative serology for HIV (31.25 versus 18.12; p-value = 
0.025) and for anti-HCV (23.18 versus 14.44; p-value = 0.017), 
and between patients with mild hemophilia when compared 
317
Health-related quality of life in hemophilia: results of the Hemophilia-Specific Quality of Life Index (Haem-a-Qol) at a Brazilian blood center
Rev Bras Hematol Hemoter. 2013;35(5):314-8
the need for greater precautions with this population, who may 
experience serious post-traumatic bleeding events, and end up 
being unprepared to recognize them and deal with the situation(19).
In some dimensions the HRQoL averages were higher 
among patients with moderate hemophilia than among those with 
severe hemophilia confirming the wide clinical variability among 
patients with moderate hemophilia(20).
In general, participants reported that the questions presented 
in the Haem-A-QoL were understandable and relevant in the 
context of hemophilia. Only one question in the ‘Self-perception’ 
dimension provoked doubts as to its interpretation. This was due 
to the use of words with a negative sense in both the question 
and the answer, which in Portuguese creates a conflict of ideas, 
because when one denies a denial, it seems to be invalidated.
As in the Turkish study, the dimension ‘Sports and Leisure’ 
attained the highest average, a repercussion of the high prevalence of 
arthropathy found in these patients. With the increased availability 
of clotting factor concentrates for treatment, the old practice of 
keeping people with hemophilia away from physical activities 
to prevent traumatic joint injuries needs to be forgotten. There 
is an increasingly well-supported tendency to encourage people 
with hemophilia to engage in sporting activities, not only for the 
physical benefits, but also as a mechanism for social inclusion(21,22).
It is noteworthy that the dimension ‘Work and School’ 
presented one of the lowest averages, which means a low loss of 
HRQoL in this dimension. However, 51.3% of the participants 
were receiving, at the time of the study, some form of social 
security benefit since they were considered unable to work. This 
discrepancy can be explained by the fact that the Haem-A-QoL 
questionnaire only evaluates the situation in the month preceding 
the study, and includes the option ‘not applicable’ for patients who 
were not involved in work or study situations during this period. 
This allowed a large percentage of invalid responses for this 
question (33.7%) thereby understating the real damage caused in 
the lives of these patients, most of whom are of working age.
The mean for the ‘Treatment’ dimension in this study 
(35.47) was better than that in the study conducted in Turkey 
(54.8), where the treatment of hemophilia is performed in general 
hospitals(18). It is believed that the availability of clotting factor 
concentrates and the existence of specialized services for the 
treatment of clotting disorders are responsible for the improved 
quality of care provided to the patients in the present study(23).
The variability in the consumption of clotting factor 
concentrates was very broad, even among patients with the same 
severity of hemophilia. It is not known to what extent patients’ 
difficulty of access to the blood center may have been responsible 
for these differences. However, in a global analysis, the average 
consumption of factor VIII concentrate by those with hemophilia 
A in the prior 12 months was 45,975.75 IU, slightly higher 
than the 40,000 IU recommended by the World Federation of 
Hemophilia to maintain moderate levels of treatment(24). 
Over 70% of the patients with severe or moderate hemophilia 
were trained to perform home treatment, indicating good coverage by 
the program which periodically seeks to add new patients and families. 
At the time of the study, physical therapy had not yet been incorporated 
as routine care provided to patients with hemophilia, even though it is 
considered essential in the rehabilitation of these individuals(25).
Table 3 - Hemophilia patient demographic, socioeconomic, and clinical 
variables associated with the Hemophilia-Specific Quality of Life (Haem-





Personal income in the previous month
Up to minimum wage 24.80 0.007
More than minimum wage 14.95











Present 24.56 < 0.001
Absent 9.75
to those with severe hemophilia (5.00 versus 15.73; p-value < 
0.001) or with moderate hemophilia (5.88 versus 15.81; p-value 
= 0.001). No statistically significant difference was found in the 
Haem-A-QoL mean scores between patients with severe and 
moderate hemophilia (14.67 versus 17.25; p-value = 0.446).
The Haem-A-QoL total score showed a significant inverse 
correlation with the consumption of factor concentrates in the 
previous 12 months. The Spearman correlation coefficient was r = 
- 0.005 (p-value < 0.001). There was no correlation between patient 
age and the Haem-A-QoL score (r = 0.538; p-value = 0.727).
Discussion
It is recognized that many researchers have devoted their 
energy to the development and validation of multiple questionnaires 
for assessing HRQoL in hemophilia(6). However, few results of the 
application of these instruments have been published. In Brazil, 
three studies have been conducted, two of which used generic 
questionnaires such as the World Health Organization Quality of 
Life Assessment (WHO-QOL)(16) and the SF-36(2), and only one 
used a specific questionnaire for patients with hemophilia(17). As to 
the application of the Haem-A-QoL, only one study, conducted in 
Turkey in 2010, has been published in the scientific world(18).
The Brazilian version of the Haem-A-QoL proved to be a 
reliable instrument to assess HRQoL in adults with hemophilia. 
The internal consistency of the questionnaire attained a 
critical alpha value of 0.70. However, this value was very low 
in the ‘Coping’ dimension. The discrepant average found in 
this dimension may reflect ignorance of the disease and its 
complications by those with the mild form of hemophilia, a 
result of the scant guidance given to such individuals who, in 
general, do not exhibit spontaneous bleeding. This fact points to 
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Conclusion
The HRQoL in hemophilia, measured by the Haem-A-QoL 
instrument, was influenced by the presence of arthropathy and 
infectious diseases transmitted by blood products. The Brazilian 
version of the Haem-A-QoL proved to be a reliable instrument and 
exhibited good discriminant validity between clinical subgroups, 
but did not adequately reveal the impact of hemophilia on patients’ 
capacity to work. As clotting factor concentrates are more widely 
available, physical activity, physiotherapy, and other rehabilitation 
measures should be encouraged in order to reduce the morbidity 
imposed by hemophilic arthropathy, and thus improve the health-
related quality of life for people with hemophilia.
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